>>June

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.

By | June 3rd, 2018|

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

By | June 3rd, 2018|

YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results

Genosco's pipeline GNS-1480 (YH25448) was presented at ASCO 2018. *ASCO stands for American Society of Clinical Oncology Annual Meeting.

By | June 3rd, 2018|
Load More Posts